Trial Profile
Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) A Randomized, Controlled, Double-blind, Parallel Group, Proof-of-concept Trial EDITA
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Proof of concept; Therapeutic Use
- Acronyms EDITA
- 17 Apr 2020 Status changed from active, no longer recruiting to completed.
- 19 Sep 2018 Results presented at the 28th Annual Congress of the European Respiratory Society
- 24 Nov 2017 Planned End Date changed from 1 Dec 2016 to 1 Jul 2018.